The resident of the SEZ of Moscow received the support of the city for the development of the production of biotechnological pharmaceutical substances and drugs

The capital's pharmaceutical company Amedart, a resident of the Technopolis Moscow special economic zone, took advantage of the interest rate compensation program for an investment loan from the Moscow Fund for Industry and Entrepreneurship Support. The funds are intended to launch the production of biotechnological pharmaceutical substances and drugs. This was announced by Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry.

The company produces Russian highly effective medicines: antitumor, antiretroviral, antidiabetic, antibiotics and others.

"On behalf of the Mayor of Moscow, the city pays special attention to the pharmaceutical industry. Effective mechanisms are in place for enterprises that promote the development of new directions and expand the range of products. Thus, with the help of the interest rate compensation program from the Moscow Fund for Industry and Entrepreneurship Support, the capital company will launch the production of biotechnological pharmaceutical substances and medicines on the territory of the Technopolis Moscow special economic zone," Maxim Liksutov said.

The total investment will exceed 800 million rubles. The project will create more than 100 new high-tech jobs.

The loan servicing compensation mechanism allows you to reduce the interest rate by half of the key rate.

"Since 2022, under this program, the Fund has helped more than 170 companies raise over 300 billion rubles. Among them are manufacturers of medicines, food, automotive components and representatives of other industries. Thanks to this support, they can modernize production facilities, introduce innovative technologies and create new jobs," said Anatoly Garbuzov, Minister of the Moscow Government and Head of the Department of Investment and Industrial Policy.

To receive compensation, it is necessary to conclude a loan agreement with the bank, then apply to the Moscow Fund for Support of Industry and Entrepreneurship.

After approval, a financial support agreement is drawn up providing for compensation of part of the interest expenses. In the future, depending on the schedule of interest write-off, the corresponding funds will be transferred to the company's account at the bank where the loan is opened.

According to Andrey Kolokoltsov, CEO of Amedart, thanks to the support of the city, the manufacturer can expand its facilities and introduce advanced technologies into the production process, actively invest in infrastructure and drug development, as well as launch new directions. Thus, the products created in the capital remain competitive in the Russian pharmaceutical market.

Sberbank provided the loan funds to the investor.

As Herman Barg, chairman of Sberbank's Moscow bank, emphasized, conditions are consistently being created in the capital under which high—tech enterprises can launch and scale complex projects, from ideas to mass production. Preferential financing conditions allow businesses to invest in equipment upgrades and the introduction of new advanced solutions. BEAC, for its part, actively supports the initiatives of the Moscow Government aimed at developing the industrial and scientific potential of the capital. As part of the relevant city program, we have already made decisions on financing Moscow enterprises and organizations in the amount of over 255 billion rubles.

Earlier, Sergei Sobyanin said that in the first 11 months of 2025, drug production in the city increased by 11.8 percent compared to the same period in 2024. At the same time, special attention is being paid to biopharma in the industry today. This area opens up new possibilities for the treatment of complex diseases, from oncological and autoimmune pathologies to rare genetic disorders.